drugset / Trial / NCT05490316
A Study of IBI353 (Orismilast) in Chinese Healthy Adults
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a first in Chinese population study to evaluate the safety, tolerability, PK and PD of multiple dose of modified-release IBI353 administered orally in healthy subjects. The study enrolls 20 healthy subjects and consists of 1 week of screening, 3 weeks of treatment period and 1 week of safety follow up after completion of last dose.
Timeline
- Start
- 2022-11-30
- Primary completion
- 2022-11-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI353 | Unknown | — | Oral |
Indications
No indication recorded.